Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines

Amira Mahdi

doi:10.1158/1538-7445.SABCS22-P1-11-10

Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines

School of Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English (Ireland)
Pages (from-to)	-
Journal	Cancer Research
DOIs	https://doi.org/10.1158/1538-7445.SABCS22-P1-11-10
Publication status	Published - 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1538-7445.SABCS22-P1-11-10

Cite this

@article{035c4c3370df42768bbd7fec9a49a750,

title = "Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines",

author = "Amira Mahdi",

year = "2023",

doi = "10.1158/1538-7445.SABCS22-P1-11-10",

language = "English (Ireland)",

pages = "--",

journal = "Cancer Research",

issn = "0008-5472",

}

TY - JOUR

T1 - Reversible versus irreversible tyrosine kinase inhibitors (TKIs) combined with antibody-drug conjugates (ADCs) in HER2-positive (HER2+) breast cancer (BC) cell lines

AU - Mahdi, Amira

PY - 2023

Y1 - 2023

U2 - 10.1158/1538-7445.SABCS22-P1-11-10

DO - 10.1158/1538-7445.SABCS22-P1-11-10

M3 - Article

SN - 0008-5472

SP - -

JO - Cancer Research

JF - Cancer Research

ER -